- Home
- PHK vs FTRE Comparison
PHK vs FTRE Comparison
Compare PHK & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHK | FTRE |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.0M | 829.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PHK | FTRE |
|---|---|---|
| Price | $4.52 | $13.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 614.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $4.41 | $3.97 |
| 52 Week High | $5.04 | $18.67 |
Technical Indicators
Market Signals| Indicator | PHK | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 32.54 | 59.26 |
| Support Level | $4.41 | $8.85 |
| Resistance Level | $4.91 | $18.26 |
| Average True Range (ATR) | 0.05 | 0.82 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 2.08 | 54.77 |
Price Performance
Historical ComparisonAbout PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. The secondary objective of the company is to seek capital appreciation.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.